Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 9061-9070 Newer>

Chemistry World March 25, 2015 Dennis Lendrem	Be careful what you wish for There is a big debate right now in the pharmaceutical industry, and specifically about measuring R&D productivity. It all comes down to a choice of metrics.
Chemistry World March 23, 2015 Andrew Turley	23andMe jumps into drug R&D 23andMe plans to create a therapeutics group that will search for new leads using its database as a research platform.
Fast Company Neal Ungerleider	Old People Saw White And Gold, And More Insights From A 23andMe Study Of #TheDress The maker of a popular genetics kit 23andMe has issued a new report on "The Dress," and why it appears differently to different people.
Chemistry World March 16, 2015 Rebecca Trager	Drug firms warned to be honest with investors The US Securities and Exchange Commission is concerned that too many pharmaceutical companies aren't being sufficiently transparent with investors about their interactions with regulators at the US Food and Drug Administration.
Chemistry World March 13, 2015 Rebecca Trager	Amgen to axe 300 Onyx employees US biotech Amgen plans to shutter the south San Francisco, US facility of Onyx Pharmaceuticals, the oncology specialist that it acquired in September 2013.
Fast Company John Paul Titlow	23andMe Wants To Turn Your DNA Data Into Lucrative New Drugs 23andMe's original business model may have been thwarted by the feds, but that isn't stopping the company from trying new ways to generate revenue. Its latest idea could be a lucrative one: invent new drugs.
AskMen.com March 11, 2015 Tyson Lowrie	Does Homeopathy Work? Today Australia's National Health and Medical Research Council dropped a bit of a surprise: they declared that homeopathy is basically useless.
Chemistry World March 11, 2015 Rebecca Trager	Mergers and moves trigger pharma layoffs Downsizing in the pharmaceutical industry is discussed.
Chemistry World March 10, 2015 Rebecca Trager	US approves biosimilar filgrastim Sandoz's Zarxio is a generic version of filgrastim, which Amgen markets as Neupogen.
Chemistry World March 10, 2015 Anmdrew Turley	AbbVie to buy Pharmacyclics for pipeline boost AbbVie has agreed to buy US biotech Pharmacyclics for $21 billion in a bid to re-stock its pipeline.
<Older 9061-9070 Newer> Return to current articles.